Detalles de la búsqueda
1.
Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab.
J Allergy Clin Immunol
; 143(6): 2158-2169, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30578873
2.
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Lancet
; 389(10080): 1699-1709, 2017 04 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-28411872
3.
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.
J Allergy Clin Immunol
; 136(1): 116-124.e7, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25769911
4.
Population pharmacokinetic-pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC).
CPT Pharmacometrics Syst Pharmacol
; 2024 Mar 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38528813
5.
Exposure-Response Analyses of Polysomnography and Subjective Sleep Efficacy End Points From the Phase 3 Trials of Lemborexant, a Dual Orexin Receptor Antagonist for the Treatment of Insomnia.
J Clin Pharmacol
; 63(4): 498-511, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36524428
6.
Opportunities and Challenges of Disease Progression Modeling in Drug Development - An IQ Perspective.
Clin Pharmacol Ther
; 114(2): 266-274, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36802040
7.
Model-Based Analysis of the Influence of Alcohol Use and Age on Pharmacokinetics-Pharmacodynamics of Oral Oxycodone in Middle-Age and Older Community-Dwelling Adults.
J Clin Pharmacol
; 62(9): 1177-1190, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35394079
8.
Risk-Based Pharmacokinetic and Drug-Drug Interaction Characterization of Antibody-Drug Conjugates in Oncology Clinical Development: An International Consortium for Innovation and Quality in Pharmaceutical Development Perspective.
Clin Pharmacol Ther
; 112(4): 754-769, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34657311
9.
Physiologically-based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors.
CPT Pharmacometrics Syst Pharmacol
; 10(5): 455-466, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33704920
10.
Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy Adults.
Clin Pharmacol Drug Dev
; 10(2): 153-165, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32468649
11.
Evaluation of the CYP3A and CYP2B6 Drug-Drug Interaction Potential of Lemborexant.
Clin Pharmacol Drug Dev
; 10(6): 681-690, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33455055
12.
Dexmedetomidine Pharmacokinetics in Neonates with Hypoxic-Ischemic Encephalopathy Receiving Hypothermia.
Anesthesiol Res Pract
; 2020: 2582965, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32158472
13.
Population Pharmacokinetics and Exposure-Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder.
J Clin Pharmacol
; 60(12): 1642-1654, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32666570
14.
Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.
Clin Pharmacol Ther
; 79(5): 461-79, 2006 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-16678548
15.
Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies.
Clin Pharmacokinet
; 44(7): 731-51, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-15966756
16.
Chronic maternal methanol inhalation in nonhuman primates (Macaca fascicularis): exposure and toxicokinetics prior to and during pregnancy.
Neurotoxicol Teratol
; 26(2): 201-21, 2004.
Artículo
en Inglés
| MEDLINE | ID: mdl-15019954
17.
Modeling dropout from adverse event data: impact of dosing regimens across pregabalin trials in the treatment of generalized anxiety disorder.
J Clin Pharmacol
; 51(5): 706-18, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-20663989
18.
Models for event-driven data: longitudinal daily adverse event and dropout.
J Clin Pharmacol
; 50(9 Suppl): 58S-62S, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20881219
19.
Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.
Drug Metab Dispos
; 32(4): 447-54, 2004 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-15039299
20.
Kinetics of B, CD4 T, and CD8 T cells infused into humans: estimates of intravascular:extravascular ratios and total body counts.
Clin Immunol
; 102(3): 249-57, 2002 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-11890711
Resultados
1 -
20
de 20
1
Próxima >
>>